EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study ( JABS )

M John iD, L Williams, G Nolan, M Bonnett, A Castley, D Nolan

HIV Medicine · 2024

DOI: 10.1111/hiv.13647 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift HIV Medicine, 2024. Verfasst von M John und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia, Australia. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Feasibility Studies, Pyridones. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ViiV Healthcare investigator-sponsored research programme, ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The inJectable Antiretroviral feasiBility Study (JABS) aimed to evaluate the implementation of long‐acting regimens in a ‘real world’ Australian setting, with inclusion of participants with complex medical needs, social vulnerability and/or historical non‐adherence.

Methods

JABS was a 12‐month, single‐centre, single‐arm, open‐label phase IV study of long‐acting cabotegravir 600 mg plus rilpivirine 900 mg administered intramuscularly every 2 months to adults with treated HIV‐1 infection. The primary endpoint was the proportion of attendances and administration of injections within a 14‐day dosing window over 12 months, out of the total prescribed doses. Secondary endpoints included proportions of missed appointments, use of oral bridging, discontinuations, virological failures, adverse events and participant‐reported outcomes. A multidisciplinary adherence programme embedded in the clinical service known as REACH provided support to JABS participants.

Results

Of 60 participants enrolled by May 2022, 60% had one or more complexity or vulnerability factors identified, including absence of social supports (50%), mental health issues, alcohol or drug use (30%) and financial hardship or instability (13%), among others. Twenty‐seven per cent of participants had historical non‐adherence to antiretroviral therapy. Out of 395 prescribed doses, 97.2% of injections were administered within correct dosing windows at clinic visits. Two courses of short‐term oral bridging were required. The rate of injection site reactions was 29%, the majority being grade 1–2. There were no virological failures, no serious adverse events and only one injection‐related study discontinuation. High baseline treatment satisfaction and acceptability of injections increased by month 12. Those with vulnerability factors had similar adherence to injections as those without such factors. Ninety‐eight per cent of the participants who completed 12 months on the study have maintained long‐acting therapy, virological suppression and retention in care.

Conclusions

Long‐acting cabotegravir plus rilpivirine was associated with very high adherence, maintenance of virological suppression, safety and treatment satisfaction in a diverse Australian clinic population, comparable to results of phase III randomized clinical trials. Individuals with vulnerability factors can achieve adherence to injections with individualized support. Long‐acting therapies in this group can increase the subsequent engagement in clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RilpivirineHIV InfectionsFeasibility StudiesPyridonesDrug MonitoringHumansMaleFemaleAdultMiddle AgedInjections, IntramuscularAnti-HIV AgentsAustraliaTreatment OutcomeHIV-1Diketopiperazines

Stichwörter der Autor:innen

adherenceinjectable ARTlong‐acting ARTreal‐worldvulnerable populations

Substanzen

cabotegravirRilpivirinePyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Department of Clinical Immunology, Royal Perth Hospital, Perth, Western Australia, Australia.
  • Immunology, PathWest, Murdoch, Western Australia, Australia.
  • Medical Genomics IIID, Murdoch University, Murdoch, Western Australia, Australia.

ORCID-Profile: M John

Förderung

  • ViiV Healthcare investigator-sponsored research programme
  • ViiV Healthcare

Zitieren

APA

John, M., Williams, L., Nolan, G., Bonnett, M., Castley, A., & Nolan, D. (2024). Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study ( JABS ). HIV Medicine. https://doi.org/10.1111/hiv.13647

Vancouver

John M, Williams L, Nolan G, Bonnett M, Castley A, Nolan D. Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study ( JABS ). HIV Medicine. 2024. doi:10.1111/hiv.13647

BibTeX
@article{John2024,
  author = {John, M and Williams, L and Nolan, G and Bonnett, M and Castley, A and Nolan, D},
  title = {Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study ( JABS )},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13647}
}
Kostenlos starten →